Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

Adam Scott Feldman, MD, MPH
Published: Friday, Aug 18, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.
 


Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x